Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France
Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France
复制标题
DOI：
10.1093/jac/dkq380
复制
发表时间：
2010-12-01
影响因子：
5.2
通讯作者：
Costagliola, Dominique
中科院分区：
文献类型：
--
作者：
Descamps, Diane;Chaix, Marie-Laure;Costagliola, Dominique
估计在法国首次接受抗逆转录病毒治疗的慢性hiv -1感染患者中传播的耐药突变和非b亚型循环的流行程度。从2006年10月至2007年3月，在530名新诊断的hiv -1感染患者的样本中寻找耐药性突变。蛋白酶和逆转录酶突变是从2007年斯坦福耐药性监测名单中确定的。在466例血清阳性持续时间< 5年的患者中检测到逆转录酶和蛋白酶耐药突变。42%的患者感染非b亚型菌株（CRF02 18.3%）。具有蛋白酶或逆转录酶突变的病毒的总体流行率为10.6%（95%置信区间6.7-16.3）。蛋白酶抑制剂、核苷类逆转录酶抑制剂和非核苷类逆转录酶抑制剂耐药相关突变的患病率分别为4.7%、5.8%和2.8%。B型（9.5%）和非B型（CRF02 7.8%，其他11.2%）感染患者的耐药频率无差异。性别、年龄、传播群体、传播国家、疾病分期、CD4计数和病毒载量等基线特征与传播性耐药的流行率无关。2006/2007年，法国传播的耐药变异的流行率为10.6%。B型和非B型传播性耐药流行率具有可比性。非b亚型的患病率仍在上升。
To estimate the prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-1-infected patients in France.Resistance mutations were sought in samples from 530 newly diagnosed HIV-1-infected patients from October 2006 to March 2007. Protease and reverse transcriptase mutations were identified from the 2007 Stanford Resistance Surveillance list.Reverse transcriptase and protease resistance mutations were determined in 466 patients with duration of seropositivity < 5 years. 42% of patients were infected with non-B subtype strains (CRF02 18.3%). The overall prevalence of viruses with protease or reverse transcriptase mutations was 10.6% (95% confidence interval 6.7-16.3). The prevalence of protease inhibitor, nucleoside reverse transcriptase inhibitor and non-nucleoside reverse transcriptase inhibitor resistance-associated mutations was 4.7%, 5.8% and 2.8%, respectively. Frequency of resistance was not different in patients infected with B (9.5%) and non-B (CRF02 7.8% and other 11.2%) subtypes. Baseline characteristics such as gender, age, transmission group, country of transmission, disease stage, CD4 counts and viral load were not associated with the prevalence of transmitted drug resistance.In France in 2006/2007, the prevalence of transmitted drug-resistant variants was 10.6%. Prevalence of transmitted drug resistance was comparable in B and non-B subtypes. Prevalence of non-B subtypes is still rising.